Pulmonary alveolar proteinosis (PAP) is a rare respiratory disease that affects somewhere between 4 and 40 people per million worldwide. The condition causes substances such as fats and proteins ...
offering a groundbreaking solution for diagnosing autoimmune pulmonary alveolar proteinosis (aPAP), a rare lung disease. The test requires just a finger-prick blood sample and builds upon the ...
has announced the publication of a manuscript detailing long-term outcomes for molgramostim inhalation solution in patients with autoimmune pulmonary alveolar proteinosis (aPAP). The study ...
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, ...
The sisters that Neehus studied had several lung abnormalities: a history of respiratory infections, polycystic lung disease, and pulmonary alveolar proteinosis (PAP), a disorder characterized by lung ...
Our lead program, MOLBREEVI*, is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was ...
Our lead program, MOLBREEVI*, is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
Our lead program, MOLBREEVI*, is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback